FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017262317> ?p ?o ?g. }

• W2017262317 endingPage "102" @default.
• W2017262317 startingPage "92" @default.
• W2017262317 abstract "Thiazolidinediones, the antidiabetic agents such as ciglitazone, has been proved to be effective in limiting atherosclerotic events. However, the underlying mechanism remains elucidative. Ox-LDL receptor-1 (LOX-1) plays a central role in ox-LDL-mediated atherosclerosis via endothelial nitric oxide synthase (eNOS) uncoupling and nitric oxide reduction. Therefore, we tested the hypothesis that ciglitazone, the PPARγ agonist, protected endothelial cells against ox-LDL through regulating eNOS activity and LOX-1 signalling. In the present study, rat microvascular endothelial cells (RMVECs) were stimulated by ox-LDL. The impact of ciglitazone on cell apoptosis and angiogenesis, eNOS expression and phosphorylation, nitric oxide synthesis and related AMPK, Akt and VEGF signalling pathway were observed. Our data showed that both eNOS and Akt phosphorylation, VEGF expression and nitric oxide production were significantly decreased, RMVECs ageing and apoptosis increased after ox-LDL induction for 24 hrs, all of which were effectively reversed by ciglitazone pre-treatment. Meanwhile, phosphorylation of AMP-activated protein kinase (AMPK) was suppressed by ox-LDL, which was also prevented by ciglitazone. Of interest, AMPK inhibition abolished ciglitazone-mediated eNOS function, nitric oxide synthesis and angiogenesis, and increased RMVECs ageing and apoptosis. Further experiments showed that inhibition of PPARγ significantly suppressed AMPK phosphorylation, eNOS expression and nitric oxide production. Ciglitazone-mediated angiogenesis and reduced cell ageing and apoptosis were reversed. Furthermore, LOX-1 protein expression in RMVECs was suppressed by ciglitazone, but re-enhanced by blocking PPARγ or AMPK. Ox-LDL-induced suppression of eNOS and nitric oxide synthesis were largely prevented by silencing LOX-1. Collectively, these data demonstrate that ciglitazone-mediated PPARγ activation suppresses LOX-1 and moderates AMPK/eNOS pathway, which contributes to endothelial cell survival and function preservation." @default.
• W2017262317 created "2016-06-24" @default.
• W2017262317 creator A5008722057 @default.
• W2017262317 creator A5013946815 @default.
• W2017262317 creator A5040862416 @default.
• W2017262317 creator A5041746925 @default.
• W2017262317 creator A5053743858 @default.
• W2017262317 creator A5078164215 @default.
• W2017262317 date "2014-11-11" @default.
• W2017262317 modified "2023-10-17" @default.
• W2017262317 title "A protective role of ciglitazone in ox‐ <scp>LDL</scp> ‐induced rat microvascular endothelial cells <i>via</i> modulating <scp>PPAR</scp> γ‐dependent <scp>AMPK</scp> / <scp>eNOS</scp> pathway" @default.
• W2017262317 cites W1546687436 @default.
• W2017262317 cites W1547383812 @default.
• W2017262317 cites W1765582275 @default.
• W2017262317 cites W1889956147 @default.
• W2017262317 cites W1965015910 @default.
• W2017262317 cites W1975475560 @default.
• W2017262317 cites W1976709012 @default.
• W2017262317 cites W1977423544 @default.
• W2017262317 cites W1977568654 @default.
• W2017262317 cites W1978332746 @default.
• W2017262317 cites W1990578191 @default.
• W2017262317 cites W1995667312 @default.
• W2017262317 cites W1996316252 @default.
• W2017262317 cites W1996881689 @default.
• W2017262317 cites W2002945974 @default.
• W2017262317 cites W2006216384 @default.
• W2017262317 cites W2011480706 @default.
• W2017262317 cites W2014598912 @default.
• W2017262317 cites W2015366426 @default.
• W2017262317 cites W2015941089 @default.
• W2017262317 cites W2024182816 @default.
• W2017262317 cites W2029491963 @default.
• W2017262317 cites W2034498004 @default.
• W2017262317 cites W2034498483 @default.
• W2017262317 cites W2034998579 @default.
• W2017262317 cites W2036787121 @default.
• W2017262317 cites W2041627221 @default.
• W2017262317 cites W2043628281 @default.
• W2017262317 cites W2047679532 @default.
• W2017262317 cites W2048856379 @default.
• W2017262317 cites W2050466097 @default.
• W2017262317 cites W2054727930 @default.
• W2017262317 cites W2056219025 @default.
• W2017262317 cites W2058409184 @default.
• W2017262317 cites W2068820862 @default.
• W2017262317 cites W2082064915 @default.
• W2017262317 cites W2090131871 @default.
• W2017262317 cites W2091193879 @default.
• W2017262317 cites W2091263181 @default.
• W2017262317 cites W2093803942 @default.
• W2017262317 cites W2094216763 @default.
• W2017262317 cites W2103888257 @default.
• W2017262317 cites W2116104030 @default.
• W2017262317 cites W2119617266 @default.
• W2017262317 cites W2121319503 @default.
• W2017262317 cites W2121863476 @default.
• W2017262317 cites W2127322520 @default.
• W2017262317 cites W2135606776 @default.
• W2017262317 cites W2143950284 @default.
• W2017262317 cites W2148216806 @default.
• W2017262317 cites W2149896598 @default.
• W2017262317 cites W2151714741 @default.
• W2017262317 cites W2161000645 @default.
• W2017262317 cites W2165532181 @default.
• W2017262317 cites W2166406418 @default.
• W2017262317 cites W2169385813 @default.
• W2017262317 cites W2169595519 @default.
• W2017262317 cites W2172212184 @default.
• W2017262317 doi "https://doi.org/10.1111/jcmm.12463" @default.
• W2017262317 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4288353" @default.
• W2017262317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25388834" @default.
• W2017262317 hasPublicationYear "2014" @default.
• W2017262317 type Work @default.
• W2017262317 sameAs 2017262317 @default.
• W2017262317 citedByCount "46" @default.
• W2017262317 countsByYear W20172623172015 @default.
• W2017262317 countsByYear W20172623172016 @default.
• W2017262317 countsByYear W20172623172017 @default.
• W2017262317 countsByYear W20172623172018 @default.
• W2017262317 countsByYear W20172623172019 @default.
• W2017262317 countsByYear W20172623172020 @default.
• W2017262317 countsByYear W20172623172021 @default.
• W2017262317 countsByYear W20172623172022 @default.
• W2017262317 countsByYear W20172623172023 @default.
• W2017262317 crossrefType "journal-article" @default.
• W2017262317 hasAuthorship W2017262317A5008722057 @default.
• W2017262317 hasAuthorship W2017262317A5013946815 @default.
• W2017262317 hasAuthorship W2017262317A5040862416 @default.
• W2017262317 hasAuthorship W2017262317A5041746925 @default.
• W2017262317 hasAuthorship W2017262317A5053743858 @default.
• W2017262317 hasAuthorship W2017262317A5078164215 @default.
• W2017262317 hasBestOaLocation W20172623172 @default.
• W2017262317 hasConcept C11960822 @default.
• W2017262317 hasConcept C126322002 @default.
• W2017262317 hasConcept C134018914 @default.
• W2017262317 hasConcept C170493617 @default.
• W2017262317 hasConcept C178790620 @default.

• next